Program
GS-3242
A development code. Also written as “GS-3242 Tablet” and “GS-3242 Injection”.
Its studies are led by Gilead Sciences.
Furthest: phase 3, since Jul 13, 20264 company-led studies, 3 open or runningNext primary completion: Aug 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 43 open or running | phase 3since Jul 13, 2026 | May 23, 2025 | Aug 2027phase 2 · NCT07645287 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 23, 2025First study: phase 1 study in HIV-1-infectionFirst studyNCT07001319 · 27 enrolled · United States, Mexico, Thailand
- Jun 8, 2026Phase 2 study in HIV-1-infectionNCT07645287 · 175 planned · United States, Australia, Canada and more
- Jul 13, 2026Phase 3 study in HIV-1-infectionPhase 3 reachedNCT07708727 · 700 planned · United States, Canada, Germany and more
- Sep 21, 2026Phase 2 study in HIV-1 InfectionNCT07841990 · 125 planned · United States
Ahead
- Aug 2027Primary completion: phase 2 study in HIV-1 InfectionNCT07841990
- Aug 2027Primary completion: phase 2 study in HIV-1-infectionNCT07645287
- Oct 2030Primary completion: phase 3 study in HIV-1-infectionNCT07708727
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07841990HIV-1 Infection · United States | 2 | Recruiting | Aug 2027 | 125 |
| NCT07708727HIV-1-infection · United States, Canada, Germany and more | 3 | Recruiting | Oct 2030 | 700 |
| NCT07645287HIV-1-infection · United States, Australia, Canada and more | 2 | Recruiting | Aug 2027 | 175 |
| NCT07001319HIV-1-infection · United States, Mexico, Thailand | 1 | Completed | Mar 3, 2026 | 27 |
How it is read
Names in the registry
- “GS-3242 Tablet”, 2 entries
- “GS-3242 Injection”, 2 entries
- “GS-3242”, 2 entries
Codes read as this program: GS3242.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.